肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Sci Rep：新的研究或为肾透明细胞癌的预后提供更佳的方法

2017-09-04 MedSci MedSci原创

肾透明细胞癌MFI2-AS
关注

目前对肾透明细胞癌（ccRCC）的预后尚未有较好的方法，研究发现，长链非编码RNAs(lncRNAs)的表达与ccRCC的预后密切相关。因此，本研究旨在使用lncRNA的表达来预测CCRCC的复发风险。研究人员从来自The Cancer Genome Atlas 数据库的351个局部ccRCC中确定了与预后相关的lncRNAs，并在167个局部ccRCCs中进行了验证。最终，研究人员确定了lncR

目前对肾透明细胞癌（ccRCC）的预后尚未有较好的方法，研究发现，长链非编码RNAs(lncRNAs)的表达与ccRCC的预后密切相关。因此，本研究旨在使用lncRNA的表达来预测CCRCC的复发风险。

研究人员从来自The Cancer Genome Atlas 数据库的351个局部ccRCC中确定了与预后相关的lncRNAs，并在167个局部ccRCCs中进行了验证。最终，研究人员确定了lncRNA MFI2-AS1作为预测ccRCC预后的最佳因素。

验证研究中，研究人员发现，MFI2-AS1的表达与较短的无病生存率独立相关（复发危险比（HR）为3.5，P = 0.0001  ）。与单独使用MFI2-AS1（0.67）及单独使用Leibovich分类（0.66）相比，结合Leibovich分类MFI2-AS1的状态可改善复发预测效果（C指数0.70）。

侵袭性肿瘤（Leibovich≥5）患者中，与预后较好未检测到MFI2-AS1的患者相比，MFI2-AS1的表达与复发风险显著增加相关（HR 12.16，P＜0.0001  ）。与正常的组织样本相比，ccRCC肿瘤组织中MFI2-AS1的表达上调，且其高表达与癌组织转移相关。

总的来说，本研究发现，MFI2-AS1的表达可有效预测ccRCC患者的预后，值得进一步探究。

原始出处：

Ronan Flippot, Roger Mouawad, et al., Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep. 2017; 7: 8540. Published online 2017 Aug 17. doi: 10.1038/s41598-017-08363-6.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978554, encodeId=3dc219e8554b5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 16 01:30:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010056, encodeId=19ea2010056d3, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 24 18:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240840, encodeId=2ad72408403e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:50:04 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240440, encodeId=12ce24044005, content=学习了.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 04 18:44:45 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240431, encodeId=8a2f240431fb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:39 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2018-04-16 qingting

    #细胞癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1978554, encodeId=3dc219e8554b5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 16 01:30:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010056, encodeId=19ea2010056d3, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 24 18:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240840, encodeId=2ad72408403e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:50:04 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240440, encodeId=12ce24044005, content=学习了.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 04 18:44:45 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240431, encodeId=8a2f240431fb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:39 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2018-03-24 wmr111

    #透明细胞癌#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1978554, encodeId=3dc219e8554b5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 16 01:30:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010056, encodeId=19ea2010056d3, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 24 18:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240840, encodeId=2ad72408403e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:50:04 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240440, encodeId=12ce24044005, content=学习了.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 04 18:44:45 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240431, encodeId=8a2f240431fb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:39 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-05 luominglian113

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1978554, encodeId=3dc219e8554b5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 16 01:30:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010056, encodeId=19ea2010056d3, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 24 18:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240840, encodeId=2ad72408403e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:50:04 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240440, encodeId=12ce24044005, content=学习了.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 04 18:44:45 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240431, encodeId=8a2f240431fb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:39 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-04 1ddf0692m34(暂无匿称)

    学习了.值得分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1978554, encodeId=3dc219e8554b5, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Apr 16 01:30:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010056, encodeId=19ea2010056d3, content=<a href='/topic/show?id=6d13948196c' target=_blank style='color:#2F92EE;'>#透明细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94819, encryptionId=6d13948196c, topicName=透明细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 24 18:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240840, encodeId=2ad72408403e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:50:04 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240440, encodeId=12ce24044005, content=学习了.值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Sep 04 18:44:45 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240431, encodeId=8a2f240431fb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Sep 04 18:06:39 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-04 131****1460

    学习了受益匪浅

    0

相关资讯

ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好

本次ESMO年会上公布的一项研究显示，MPDL3280A(抗PDL1)联合贝伐珠单抗及化疗耐受性良好，未观察到预期外毒性反应，并且在多种肿瘤中观察到客观应答。此项开放标签、多中心、Ⅰb期研究纳入了局部晚期或转移性实体恶性肿瘤患者，并评估了MPDL3280A联合贝伐珠单抗[A组，难治性肿瘤或肾细胞癌(RCC)]以及联合贝伐珠单抗+FOLFOX(B组，未行奥沙利铂治疗肿瘤)的安全性和初步有效性。化疗采

Mol Can Thera：联合用药可有效治疗乳腺癌和肾透明细胞癌

近日，来自美国梅奥诊所的研究者通过研究揭示了一种强有力的治疗两种致命性癌症-三阴性乳腺癌和肾透明细胞癌（常见的肾癌）的方法。相关研究成果刊登在了国际杂志Molecular Cancer Therapeutics上，文章中，研究者报道了两种药物，罗咪酯肽和地西他滨，两种药物可以协作来激活肿瘤抑制基因抑制肿瘤发生。用药后，肿瘤抑制基因会分泌卷曲相关蛋白sFRP1，随后肿瘤细胞便会停止生长，并且死亡。

JCO:PET/CT可诊断肾透明细胞癌

哥伦比亚大学的Chaitanya R. Divgi等人12月3日在线出版在《临床肿瘤学杂志》（Journal of Clinical Oncology）上的一项研究结果表明：碘-124（124I）吉瑞昔单抗标记，行PET/CT可精确地以非侵入方式鉴定肾透明细胞癌（ccRCC）。该研究是世界上首个针对恶性肿瘤临床验证试验：用生物标记物分子标记，通过正